![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
14分
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko Cell & Gene: The Podcast
-
- 生命科学
We love to hear from our listeners. Send us a message.Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.
We love to hear from our listeners. Send us a message.Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.
14分